Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

57.79
Delayed Data
As of Jan 19
 +1.28 / +2.27%
Today’s Change
32.83
Today|||52-Week Range
57.82
+7.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$113.7B

Company Description

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085

Employees

Shareholders

Other institutional6.15%
Mutual fund holders1.92%
Individual stakeholders--

Top Executives

Lars Fruergaard JørgensenPresident & Chief Executive Officer
Maziar Mike DoustdarExecutive Vice President-International Operations
Jesper BrandgaardChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Lars GreenExecutive VP, Head-Business Services & Compliance